LUCIANA BAHIA

LUCIANA BAHIA


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
LBLUCIANA BAHIA
LUCIANA BAHIA
ECEvandro Silva Freire Coutinho
Evandro Silva Freire Coutinho
LBLaura Augusta Barufaldi
Laura Augusta Barufaldi
GAGabriela de Azevedo Abreu
Gabriela de Azevedo Abreu
TMThainá Alves Malhão
Thainá Alves Malhão
DADenizar Vianna Araujo
Denizar Vianna Araujo
Obesity is a major global epidemic and a burden to society and health systems. It is well known risk factor for a number of chronic medical conditions with high morbidity and mortality. This study aimed to provide an estimate of the direct costs associated to outpatient and inpatient care of overweight and obesity related diseases in the perspective of the Brazilian Health System (SUS).

CTCristiana M Toscano
Cristiana M Toscano
TSTatiana H. Sugita
Tatiana H. Sugita
MMICHELLE ROSA
MICHELLE ROSA
HPHermelinda C. Pedrosa
Hermelinda C. Pedrosa
RRRoger Rosa
Roger Rosa
LBLUCIANA BAHIA
LUCIANA BAHIA
The aim of this study was to estimate the annual costs for the treatment of diabetic foot disease (DFD) in Brazil. We conducted a cost-of-illness study of DFD in 2014, while considering the Brazilian Public Healthcare System (SUS) perspective. Direct medical costs of outpatient management and inpatient care were considered. For outpatient costs, a panel of experts was convened from which utilization of healthcare services for the management of DFD was obtained. When considering the range of syndromes included in the DFD spectrum, we developed four well-defined hypothetical DFD cases: (1) peripheral neuropathy without ulcer, (2) non-infected foot ulcer, (3) infected foot ulcer, and (4) clinical management of amputated patients. Quantities of each healthcare service was then multiplied by their respective unit costs obtained from national price listings. We then developed a decision analytic tree to estimate nationwide costs of DFD in Brazil, while taking into the account the estimated cost per case and considering epidemiologic parameters obtained from a national survey, secondary data, and the literature. For inpatient care, ICD10 codes related to DFD were identified and costs of hospitalizations due to osteomyelitis, amputations, and other selected DFD related conditions were obtained from a nationwide hospitalization database. Direct medical costs of DFD in Brazil was estimated considering the 2014 purchasing power parity (PPP) (1 Int$ = 1.748 BRL). We estimated that the annual direct medical costs of DFD in 2014 was Int$ 361 million, which denotes 0.31% of public health expenses for this period. Of the total, Int$ 27.7 million (13%) was for inpatient, and Int$ 333.5 million (87%) for outpatient care. Despite using different methodologies to estimate outpatient and inpatient costs related to DFD, this is the first study to assess the overall economic burden of DFD in Brazil, while considering all of its syndromes and both outpatients and inpatients. Although we have various reasons to believe that the hospital costs are underestimated, the estimated DFD burden is significant. As such, public health preventive strategies to reduce DFD related morbidity and mortality and costs are of utmost importance.

3 January 2019 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
KMKarla F. S. Melo
Karla F. S. Melo
LBLUCIANA BAHIA
LUCIANA BAHIA
BPBruna Pasinato
Bruna Pasinato
GPGustavo J. M. Porfirio
Gustavo J. M. Porfirio
AMAna Luiza Martimbianco
Ana Luiza Martimbianco
BSBeatriz Schaan
Beatriz Schaan
Strict glucose control using multiple doses of insulin is the standard treatment for type 1 diabetes mellitus (T1DM), but increased risk of hypoglycemia is a frequent drawback. Regular insulin in multiple doses is important for achieving strict glycemic control for T1DM, but short-acting insulin analogues may be better in reducing hypoglycemia and postprandial glucose levels. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the effects of short-acting insulin analogues vs regular human insulin on hypoglycemia and postprandial glucose in patients with T1DM. Searches were run on the electronic databases MEDLINE, Cochrane-CENTRAL, EMBASE, ClinicalTrials.gov, LILACS, and DARE for RCTs published until August 2017. To be included in the study, the RCTs had to cover a minimum period of 4 weeks and had to assess the effects of short-acting insulin analogues vs regular human insulin on hypoglycemia and postprandial glucose levels in patients with T1DM. Two independent reviewers extracted the data and assessed the quality of the selected studies. The primary outcomes analyzed were hypoglycemia (total episodes, nocturnal hypoglycemia, and severe hypoglycemia) and postprandial glucose (at all times, after breakfast, after lunch, and after dinner). Glycated hemoglobin (HbA1c) levels and quality of life were considered secondary outcomes. The risk of bias of each RCT was assessed using the Cochrane Collaboration Risk of Bias table, while the quality of evidence for each outcome was assessed using the GRADEpro software. The pooled mean difference in the number of hypoglycemic episodes and postprandial glucose between short-acting insulin analogues vs. regular human insulin was calculated using the random-effects model. Of the 2897 articles retrieved, 22 (6235 patients) were included. Short-acting insulin analogues were associated with a decrease in total hypoglycemic episodes (risk rate 0.93, 95% CI 0.87–0.99; 6235 patients; I2 = 81%), nocturnal hypoglycemia (risk rate 0.55, 95% CI 0.40–0.76, 1995 patients, I2 = 84%), and severe hypoglycemia (risk rate 0.68, 95% CI 0.60–0.77; 5945 patients, I2 = 0%); and with lower postprandial glucose levels (mean difference/MD − 19.44 mg/dL; 95% CI − 21.49 to − 17.39; 5031 patients, I2 = 69%) and lower HbA1c (MD − 0,13%; IC 95% − 0.16 to − 0.10; 5204 patients; I2 = 73%) levels. Short-acting insulin analogues are superior to regular human insulin in T1DM patients for the following outcomes: total hypoglycemic episodes, nocturnal hypoglycemia, severe hypoglycemia, postprandial glucose, and HbA1c.

MMICHELLE ROSA
MICHELLE ROSA
RRRoger Rosa
Roger Rosa
MCMarcelo G. Correia
Marcelo G. Correia
DADenizar V. Araujo
Denizar V. Araujo
LBLUCIANA BAHIA
LUCIANA BAHIA
CTCristiana M Toscano
Cristiana M Toscano
Diabetes is associated with a significant burden globally. The costs of diabetes-related hospitalizations are unknown in most developing countries. The aim of this study was to estimate the total number and economic burden of hospitalizations attributable to diabetes mellitus (DM) and its complications in adults from the perspective of the Brazilian Public Health System in 2014. Data sources included the National Health Survey (NHS) and National database of Hospitalizations (SIH). We considered diabetes, its microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications (coronary heart disease, cerebrovascular disease, and peripheral arterial disease), respiratory and urinary tract infections, as well as selected cancers. Assuming that DM patients are hospitalized for these conditions more frequently that non-DM individuals, we estimated the etiological fraction of each condition related to DM, using the attributable risk methodology. We present number, average cost per case, and overall costs of hospitalizations attributable to DM in Brazil in 2014, stratified by condition, state of the country, gender and age group. In 2014, a total of 313,273 hospitalizations due to diabetes in adults were reported in Brazil (4.6% of total adult hospitalization), totaling (international dollar) Int$264.9 million. The average cost of an adult hospitalization due to diabetes was Int$845, 19% higher than hospitalization without DM. Hospitalizations due to cardiovascular diseases related to diabetes accounted for the higher proportion of costs (47.9%), followed by microvascular complications (25.4%) and DM per se (18.1%). Understanding the costs of diabetes and its major complications is crucial to raise awareness and to support the decision-making process on policy implementation, also allowing the assessment of prevention and control strategies.

1 July 2019 in Jornal de Pediatria
Verified
Journal Article
Open access
LBLUCIANA BAHIA
LUCIANA BAHIA
CSCamila Wohlgemuth Schaan
Camila Wohlgemuth Schaan
KSKaren Sparrenberger
Karen Sparrenberger
GAGabriela de Azevedo Abreu
Gabriela de Azevedo Abreu
LBLaura Augusta Barufaldi
Laura Augusta Barufaldi
BSBeatriz Schaan
Beatriz Schaan
This study aimed to assess the quality of systematic reviews on prevention and non-pharmacological treatment of overweight and obesity in children and adolescents. A search was done in electronic databases (Medline via PubMed, Web of Science, Scopus, LILACS, the Cochrane Library, and Clinical Trials), including only systematic reviews with meta-analysis. Reviews were selected by two researchers, and a third one solved the divergences. PRISMA statement and checklist were followed. A total of 4574 records were retrieved, including 24 after selection. Six reviews were on obesity prevention, 17 on obesity treatment, and one on mixed interventions for prevention and treatment of obesity. The interventions were very heterogeneous and showed little or no effects on weight or body mass index. Mixed interventions that included dieting, exercise, actions to reduce sedentary behavior, and programs involving the school or families showed some short-term positive effects. Reviews that analyzed cardiovascular risk factors demonstrated significant improvements in the short-term. The systematic reviews of interventions to prevent or reduce obesity in children and adolescents generally showed little or no effects on weight or body mass index, although cardiovascular profile can be improved. Mixed interventions demonstrated better effects, but the long-term impact of obesity treatments of children and adolescents remains unclear.

27 September 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar
VGViviane Zorzanelli Rocha Giraldez
Viviane Zorzanelli Rocha Giraldez
ABAdriana Bertolami
Adriana Bertolami
RSRaul D Santos
Raul D Santos
ALAna Maria Lottenberg
Ana Maria Lottenberg
WSWilson Salgado
Wilson Salgado
Introdução A hipercolesterolemia familiar (HF) é uma causa genética comum de doença coronariana prematura, especialmente de infarto do miocárdio, devido à exposição ao longo da vida a concentrações elevadas de colesterol da lipoproteína de baixa densidade (LDL-c). Caracteriza-se por ser uma forma grave de dislipidemia de base genética, em que aproximadamente 85% dos homens e 50% das mulheres podem ter um evento coronariano antes de completar os 65 anos de idade, se não tratados adequadamente. A HF é considerada um [...] Introdução A hipercolesterolemia familiar (HF) é uma causa genética comum de doença coronariana prematura, especialmente de infarto do miocárdio, devido à exposição ao longo da vida a concentrações elevadas de colesterol da lipoproteína de baixa densidade (LDL-c). Caracteriza-se por ser uma forma grave de dislipidemia de base genética, em que aproximadamente 85% dos homens e 50% das mulheres podem ter um evento coronariano antes de completar os 65 anos de idade, se não tratados adequadamente. A HF é considerada um